Over two thirds of patients with hidradenitis suppurativa experience fewer flares, new lesions, and improved quality of life ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

About The Study: In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated with increased risk of psychiatric adverse ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...